Know Your Investor: Deep Track Capital (June’25 Edition)

Shots:    Welcome to the 2025 edition of Know Your Investor, highlighting top venture capital firms driving healthcare innovation This edition features Deep Track Capital, a firm dedicated to investing in life sciences companies that are advancing innovations to improve public health In 2024, Deep Track Capital invested approximately $4.35B across six funding rounds, adding 32…

ByPrince GiriJune 5, 2025

News

Geron Receives the EC’s Approval for Rytelo (Imetelstat) to Treat Transfusion-Dependent Anemia due to Lower-Risk MDS

Shots:The EC has approved Rytelo to treat TD anemia in adults with very low, low, or intermediate risk non-del(5q) MDS, unresponsive or ineligible for erythropoietin-based therapy in 30 EEA states; commercialization to begin in select EU states by 2026 pending country-by-country reimbursement Approval was based on P-III (IMerge) study of Rytelo vs PBO…

ByRidhi RastogiMarch 12, 2025

News

Geron Receives Positive CHMP Opinion for Rytelo (Imetelstat) to Treat Transfusion-Dependent Anemia due to Lower-Risk MDS

Shots: The CHMP has recommended Rytelo to treat TD anemia in adults with very low, low, or intermediate risk non-del(5q) MDS, unresponsive or ineligible for erythropoietin-based therapy, with the EC’s decision expected in the coming months Opinion was based on P-III (IMerge) study of Rytelo vs PBO that showed reduced need for RBC transfusions within…

ByDipanshu DixitDecember 13, 2024

News

Geron’s Rytelo (Imetelstat) Gains the US FDA’s Approval to Treat Myelodysplastic Syndromes (MDS) with Transfusion-Dependent Anemia

Shots: The US FDA has approved Rytelo to treat low- to intermediate-risk MDS with transfusion-dependent (TD) anemia adults who did not respond to, lost response, or are not eligible for erythropoiesis-stimulating agents (ESA) The approval was supported by the P-III (IMerge) study of Rytelo vs PBO, depicting a 39.8% vs 15.0% RBC-TI rate for 8wks.…

ByDipanshu DixitJune 6, 2024

TOP 20

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results- change in control limitations- and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a list of…

ByPrince GiriJanuary 3, 2020

Know Your Investor: Deep Track Capital (June’25 Edition)

Geron Receives the EC’s Approval for Rytelo (Imetelstat) to Treat Transfusion-Dependent Anemia due to Lower-Risk MDS

Geron Receives Positive CHMP Opinion for Rytelo (Imetelstat) to Treat Transfusion-Dependent Anemia due to Lower-Risk MDS

Geron’s Rytelo (Imetelstat) Gains the US FDA’s Approval to Treat Myelodysplastic Syndromes (MDS) with Transfusion-Dependent Anemia

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

Contact US

OUR INFORMATION

FOLLOW US